PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 20442653-0 2010 Mitogen-activated protein kinases pathway is involved in physiological testosterone-induced tissue factor pathway inhibitor expression in endothelial cells. Testosterone 71-83 tissue factor pathway inhibitor Homo sapiens 92-123 20442653-1 2010 The mechanism of testosterone inducing the tissue factor pathway inhibitor (TFPI) in protecting against thrombosis is unknown. Testosterone 17-29 tissue factor pathway inhibitor Homo sapiens 43-74 20442653-1 2010 The mechanism of testosterone inducing the tissue factor pathway inhibitor (TFPI) in protecting against thrombosis is unknown. Testosterone 17-29 tissue factor pathway inhibitor Homo sapiens 76-80 20442653-6 2010 Blocking ERK1/2 or JNK pathway could significantly impair testosterone-induced TFPI at both translational and transcriptional levels in HUVECs. Testosterone 58-70 tissue factor pathway inhibitor Homo sapiens 79-83 20442653-7 2010 Testosterone at a physiological concentration may help to prevent thrombosis development by stimulating TFPI expression in HUVECs, partly through the ERK1/2 and JNK MAPK pathway. Testosterone 0-12 tissue factor pathway inhibitor Homo sapiens 104-108 19169266-7 2009 A concentration of 30 nmol L(-1) testosterone increased the secretion of TFPI compared with the TNF-alpha-treated group. Testosterone 33-45 tissue factor pathway inhibitor Homo sapiens 73-77 19888533-0 2009 Impact of long-term testosterone treatment on plasma levels of free TFPI and TF-induced thrombin generation ex vivo in elderly men with low testosterone levels. Testosterone 20-32 tissue factor pathway inhibitor Homo sapiens 68-72 19888533-2 2009 Recently, we demonstrated that elderly men with low testosterone levels had lower plasma levels of free tissue factor pathway inhibitor (TFPI) Ag associated with shortened tissue factor (TF)-induced coagulation initiation in a population based case-control study. Testosterone 52-64 tissue factor pathway inhibitor Homo sapiens 104-135 19888533-2 2009 Recently, we demonstrated that elderly men with low testosterone levels had lower plasma levels of free tissue factor pathway inhibitor (TFPI) Ag associated with shortened tissue factor (TF)-induced coagulation initiation in a population based case-control study. Testosterone 52-64 tissue factor pathway inhibitor Homo sapiens 137-141 19888533-3 2009 Our hypothesis was that one year of testosterone treatment to physiological levels in elderly men would increase the levels of free TFPI Ag in plasma and have a favorable effect on TF-induced coagulation. Testosterone 36-48 tissue factor pathway inhibitor Homo sapiens 132-136 19169266-9 2009 This suggests that physiological testosterone concentrations may exert their antithrombotic effects on TFPI expression during inflammation by downregulating NF-kappaB activity. Testosterone 33-45 tissue factor pathway inhibitor Homo sapiens 103-107 19277407-2 2009 Experimental studies have shown increased synthesis and release of tissue factor pathway inhibitor (TFPI) by physiological levels of testosterone in endothelial cells. Testosterone 133-145 tissue factor pathway inhibitor Homo sapiens 67-98 19169266-0 2009 Testosterone alleviates tumor necrosis factor-alpha-mediated tissue factor pathway inhibitor downregulation via suppression of nuclear factor-kappa B in endothelial cells. Testosterone 0-12 tissue factor pathway inhibitor Homo sapiens 61-92 19169266-1 2009 We have observed earlier that testosterone at physiological concentrations can stimulate tissue factor pathway inhibitor (TFPI) gene expression through the androgen receptor in endothelial cells. Testosterone 30-42 tissue factor pathway inhibitor Homo sapiens 89-120 19169266-1 2009 We have observed earlier that testosterone at physiological concentrations can stimulate tissue factor pathway inhibitor (TFPI) gene expression through the androgen receptor in endothelial cells. Testosterone 30-42 tissue factor pathway inhibitor Homo sapiens 122-126 19169266-2 2009 This study further investigated the impact of testosterone on TFPI levels in response to inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha). Testosterone 46-58 tissue factor pathway inhibitor Homo sapiens 62-66 19277407-8 2009 Multiple regression analysis revealed that total and free testosterone were independent predictors of plasma free TFPI Ag. Testosterone 58-70 tissue factor pathway inhibitor Homo sapiens 114-118 19277407-9 2009 Our findings suggest that low testosterone levels in elderly men is associated with low plasma free TFPI Ag and subsequent shortened initiation phase of TF-induced coagulation. Testosterone 30-42 tissue factor pathway inhibitor Homo sapiens 100-104 19277407-2 2009 Experimental studies have shown increased synthesis and release of tissue factor pathway inhibitor (TFPI) by physiological levels of testosterone in endothelial cells. Testosterone 133-145 tissue factor pathway inhibitor Homo sapiens 100-104 19277407-3 2009 Our hypothesis was that elderly men with low testosterone levels would have lower plasma levels of plasma free TFPI with subsequent increased thrombin generation. Testosterone 45-57 tissue factor pathway inhibitor Homo sapiens 111-115 19277407-5 2009 Elderly men with low testosterone levels had lower plasma free TFPI Ag (10.9 +/- 2.3 ng/ml vs. 12.3 +/- 3.0 ng/ml, p = 0.027) and shorter initiation phase of TF-induced coagulation assessed by lag-time (5.1 +/- 1.0 min vs. 5.7 +/- 1.3, p = 0.039). Testosterone 21-33 tissue factor pathway inhibitor Homo sapiens 63-67 17534406-0 2007 Physiological testosterone stimulates tissue plasminogen activator and tissue factor pathway inhibitor and inhibits plasminogen activator inhibitor type 1 release in endothelial cells. Testosterone 14-26 tissue factor pathway inhibitor Homo sapiens 71-102 17534406-9 2007 Testosterone at a physiologic concentration (30 nmol/L) increased the antigen levels of tPA and TFPI significantly (P < 0.05). Testosterone 0-12 tissue factor pathway inhibitor Homo sapiens 96-100 17534406-14 2007 The results demonstrated that testosterone at physiological concentrations may have a beneficial influence on the haemostatic system through enhancement of anticoagulant activity, resulting from stimulation of TFPI and tPA expression and inhibition of PAI-1 secretion by the endothelium. Testosterone 30-42 tissue factor pathway inhibitor Homo sapiens 210-214